The association between the APE1 Asp148Glu polymorphism and prostate cancer susceptibility: a meta-analysis based on case-control studies
The association between the APE1 Asp148Glu polymorphism and prostate cancer susceptibility: a meta-analysis based on case-control studies
复制标题
APE1 Asp148Glu 多态性与前列腺癌易感性之间的关联：基于病例对照研究的荟萃分析
DOI：
10.1007/s00438-014-0916-3
复制
发表时间：
2015
影响因子：
3.1
通讯作者：
Liu Chuan
中科院分区：
文献类型：
--
作者：
Zhou Xue;Wei Li;Jiao Guangjun;Gao Wei;Ying Mingzhen;Wang Ning;Wang Yajie;Liu Chuan
脱嘌呤/脱嘧啶核酸内切酶1（apurinic/apyrimidinic endonuclease 1，APE 1）在DNA损伤修复和加合物形成中起重要作用。然而，以往关于APE 1Asp 148 Glu多态性与前列腺癌易感性之间关系的病例对照研究显示了相互矛盾的结果，本荟萃分析旨在更精确地估计这种关系。共纳入7项病例对照研究进行分析，包括1，294例病例和1，762例对照。总体而言，在所有遗传模型中均未发现显著关联（GG vs. TT：OR = 1.16，95% CI 0.89-1.52; TG vs. TT：OR = 1.04，95% CI 0.81-1.35;显性模型GG + TG vs. TT：OR = 1.12，95% CI 0.96-1.30;隐性模型GG vs. TG + TT：OR = 0.90，95% CI 0.77-1.04）;在按对照来源划分的亚组中，我们发现基于医院的亚组中的主导模型具有显著相关性（OR = 1.34，95% CI 1.08-1.68），在亚组中的其他模型中未发现显著相关性。Meta分析提示APE 1Asp 148 Glu基因多态性是医院人群前列腺癌易感性的危险因素。
The apurinic/apyrimidinic endonuclease 1 (APE1) plays important roles in the repair of DNA damage and adducts. However, previous case–control studies on the association between theAPE1Asp148Glu polymorphism and prostate cancer susceptibility have shown contradictory results, this meta-analysis was performed to draw a more precise estimation of the relationship. A total of seven case–control studies including 1,294 cases and 1,762 controls were included for analysis. In overall, no significant associations were found in all genetic models (GG vs. TT: OR = 1.16, 95 % CI 0.89–1.52; TG vs. TT: OR = 1.04, 95 % CI 0.81–1.35; the dominant model GG + TG vs. TT: OR = 1.12, 95 % CI 0.96–1.30; the recessive model GG vs. TG + TT: OR = 0.90, 95 % CI 0.77–1.04); in the subgroup by source of control, we found a significant association for the dominant model in Hospital-based subgroup (OR = 1.34, 95 % CI 1.08–1.68), no significant associations were found in other models in the subgroups. This meta-analysis suggested that theAPE1Asp148Glu polymorphism was a risk factor for prostate cancer susceptibility in Hospital-based population.